Because hematologic cancers are often associated with poor prognosis, the development of new and efficacious treatments has become a national health care imperative. Recent trials of a humanized anti-CD47 monoclonal antibody (mAb) in lymphoma, multiple myeloma (MM), and other hematologic malignancies has shown great promise. However, it is also expressed on red blood cells (RBCs), thereby creating a significant impact on blood bank testing and transfusion management.
In anticipation of new anti-CD47 therapies in practice, clinical laboratory and blood bank personnel including pathologists, phlebotomists, technologists, nurses, and collections managers need to prepare for strategies that address the effects of anti-CD47 mAb therapy on RBCs, compatibility testing, and transfusion requirements.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/deciphering-the-clinical-clues-updates-to-protocols-and-procedures-for-anti-cd47-agents-in-clinical-laboratories-2/
- Start Date: 2023-10-14 05:00:00
- End Date: 2023-10-14 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Gilead Sciences, Inc. - Amount: 69000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology